REG - Celadon Pharma. PLC - Results of Feasibility Study

Celadon PharmaceuticalsAnnouncement

30/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221230:nRSd2589La&default-theme=true

RNS Number : 2589L  Celadon Pharmaceuticals PLC  30 December 2022

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Group")

 

Results of Feasibility Study Submitted to Research Ethics Committee for
Approval

 

London, 30 December 2022 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing and
sale of breakthrough cannabis-based medicines, announces that LVL Health, its
private pain clinic subsidiary, has concluded the feasibility study of its
non-cancer chronic pain clinical trial and the results have been formally
submitted to the Research Ethics Committee ("REC") in line with the timings
provided in the Interim results announced on 29 September 2022.

 

The feasibility study was designed to demonstrate LVL's ability to engage and
retain patients and was requested by REC prior to REC approval of the larger
clinical trial which would allow for the enrolment of up to 5,000 patients.
The design of the larger clinical trial has already been conditionally
approved by the MHRA and enrolment will commence upon receipt of approval from
REC.

 

James Short, CEO of Celadon, commented:

 

"The Company is pleased to confirm that its feasibility study has concluded
and we have submitted the positive results to REC. Everything we do at Celadon
starts with the patient, and the results from the study we have seen in terms
of improvements in quality of life in recent months have been tremendous. Our
longstanding aim remains, and we continue to strive, to open up the UK market
by giving doctors confidence in prescribing."

"The planned, larger clinical trial has the potential to provide the most
robust data set to-date in the UK for cannabis-based medicines. It was
designed in collaboration with the MHRA to provide a data set that will enable
the potential for prescription and reimbursement by the National Health
Service."

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts / Patrick Dolaghan          +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility comprises a laboratory designed to meet GMP standards, and
capacity for a large indoor hydroponic growing facility that has received a
Home Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved
cannabis trial using cannabis based medicinal products to treat chronic pain
in the UK. Celadon also has a minority interest in early-stage biopharma
Kingdom Therapeutics which is developing a licenced cannabinoid medicine to
treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.co.uk
(http://www.celadonpharma.co.uk)

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication
of this announcement, this information is now considered to be in the public
domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZMZZLLVGZZM